{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T13:00:43Z","timestamp":1792760443728,"version":"4.5.0"},"reference-count":8,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2008,5,1]],"date-time":"2008-05-01T00:00:00Z","timestamp":1209600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,5,1]],"date-time":"2008-05-01T00:00:00Z","timestamp":1209600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Psychiatry Research"],"published-print":{"date-parts":[[2008,5]]},"DOI":"10.1016\/j.psychres.2008.01.011","type":"journal-article","created":{"date-parts":[[2008,4,19]],"date-time":"2008-04-19T09:19:07Z","timestamp":1208596747000},"page":"250-253","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"title":["Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: A 12-week double-blind, placebo-controlled pilot study"],"prefix":"10.1016","volume":"159","author":[{"given":"Trino","family":"Baptista","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Euderruh","family":"Uzc\u00e1tegui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nairy","family":"Rangel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yamily","family":"El Fakih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana","family":"Galeazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Beaulieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enma Araujo","family":"de Baptista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.psychres.2008.01.011_bib1","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.schres.2007.03.029","article-title":"Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double-blind, placebo-controlled study","volume":"93","author":"Baptista","year":"2007","journal-title":"Schizophrenia Research"},{"key":"10.1016\/j.psychres.2008.01.011_bib2","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/sj.ijo.0803222","article-title":"Weight loss in overweight patients maintained on atypical antipsychotic agents","volume":"30","author":"Centorrino","year":"2006","journal-title":"International Journal of Obesity"},{"key":"10.1016\/j.psychres.2008.01.011_bib3","first-page":"CD005148","article-title":"Interventions to reduce weight gain in schizophrenia","volume":"24","author":"Faulkner","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1016\/j.psychres.2008.01.011_bib4","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/j.metabol.2006.08.001","article-title":"Sustainability of 8% weight loss, reduction of insulin resistance, and amelioration of atherogenic-metabolic risk factors over 4\u00a0years by metformin-diet in women with polycystic ovary syndrome","volume":"55","author":"Glueck","year":"2006","journal-title":"Metabolism"},{"key":"10.1016\/j.psychres.2008.01.011_bib5","doi-asserted-by":"crossref","first-page":"765","DOI":"10.2165\/00023210-200216110-00005","article-title":"Antipsychotic-induced venous thromboembolism: a review of the evidence","volume":"16","author":"Hagg","year":"2002","journal-title":"CNS Drugs"},{"key":"10.1016\/j.psychres.2008.01.011_bib6","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1176\/appi.ajp.162.5.954","article-title":"A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain","volume":"162","author":"Henderson","year":"2005","journal-title":"American Journal of Psychiatry"},{"issue":"Suppl 1","key":"10.1016\/j.psychres.2008.01.011_bib7","first-page":"20","article-title":"Metabolic considerations in the use of antipsychotic medications: a review of recent evidence","volume":"68","author":"Newcomer","year":"2007","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1016\/j.psychres.2008.01.011_bib8","series-title":"Pharmacotherapy of Obesity: Options and Alternatives","article-title":"Sibutramine","author":"Ryan","year":"2004"}],"container-title":["Psychiatry Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178108000152?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178108000152?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T05:19:06Z","timestamp":1759036746000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165178108000152"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5]]},"references-count":8,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2008,5]]}},"alternative-id":["S0165178108000152"],"URL":"https:\/\/doi.org\/10.1016\/j.psychres.2008.01.011","relation":{},"ISSN":["0165-1781"],"issn-type":[{"value":"0165-1781","type":"print"}],"subject":[],"published":{"date-parts":[[2008,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: A 12-week double-blind, placebo-controlled pilot study","name":"articletitle","label":"Article Title"},{"value":"Psychiatry Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.psychres.2008.01.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}